首页> 外文OA文献 >A randomized, double-blind comparison of tenofovir alafenamide versus tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine for initial HIV-1 treatment: Week 96 results

【2h】

A randomized, double-blind comparison of tenofovir alafenamide versus tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine for initial HIV-1 treatment: Week 96 results

机译：替诺福韦阿拉芬酰胺和替诺福韦富马酸替诺福韦的随机，双盲比较，每种药物与elvitegravir，cobicistat和恩曲他滨共同配制：最初的HIV-1治疗：第96周结果

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Wohl David D.; Cheret Antoine A.; Brunetta Jason J.; Mussini Cristina C.; Tebas Pablo P.; Sax Paul Edward Dward P.E.; Cheng Andrew K A.K.; Zhong Lijie L.; Callebaut Christian C.; Das Moupali M.; Fordyce Marshall M.; Oka Shinichi S.; Friborg Sandra S.; Villamejor Kathleen K.; Huang Jay J.; Guo Susan S.; Liu Hui H.; Wang Hui H.; Miller Michael M.; Margot Nicolas N.; Clumeck Nathan; Clarke Amanda A.; Brinson Cynthia C.; Stephens Jeffrey J.; Tashima Karen K.; Arribas Jose; Rashbaum Bruce B.;
展开▼
作者单位

展开▼
年度 2016
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 Results [J] . Wohl David, Oka Shinichi, Clumeck Nathan, JAIDS: Journal of acquired immune deficiency syndromes . 2016,第1期

机译：替诺福韦阿芬酯与富马酸替诺福韦地索非尔联合富马酸酯的随机，双盲比较：每种药物均与Elvitegravir，Cobicistat和Emtricitabine共同配制用于初始HIV-1治疗：第96周的结果
2. A randomized double-blind comparison of coformulated elvitegravir/ cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: Analysis of week 96 results [J] . ZolopaA., SaxP.E., DejesusE., JAIDS: Journal of acquired immune deficiency syndromes . 2013,第1期

机译：联合配制的依维格韦/ cobicistat /恩曲他滨/替诺福韦富马酸替诺福韦与依法韦仑/恩曲他滨/替诺福韦富马酸替莫韦特在HIV-1感染初始治疗中的随机双盲比较：分析第96周的结果
3. Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 Results [J] . Arribas Jose R., Thompson Melanie, Sax Paul E., JAIDS: Journal of acquired immune deficiency syndromes . 2017,第2期

机译：Tenofovir Alafenainide（TAF）对替诺福韦毒素富马酸莫特（TDF）的随机性，双盲比较，每种与ElviteGravir，Cobicistat和Emtrickabine（E / C / F）的Coformuct用于初始HIV-1治疗：周144结果
4. Cost effectiveness analysis of abacavir/lamivudine versus tenofovir/emtricitabine combination therapy as part of highly active antiretroviral therapy in treatment naive HIV-infected patients. [D] . Giguere, Pierre. 2010

机译：阿巴卡韦/拉米夫定与替诺福韦/恩曲他滨联合疗法作为高活性抗逆转录病毒疗法治疗未受HIV感染的患者的成本效益分析。
5. 1768. Efficacy and Safety of Switching From Boosted-Protease Inhibitors (bPI) Plus Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) Regimens to the Once Daily (QD) Single-Tablet Regimen (STR) of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Virologically Suppressed HIV-1-Infected Adults: Week 96 Results of the Phase 3 Randomized Non-Inferiority EMERALD Trial [O] . Joseph Eron, Chloe Orkin, Douglas Cunningham, -1

机译：1768.从强化蛋白酶抑制剂（bPI）加上恩曲他滨/替诺福韦富马酸二氯吡呋酯（F / TDF）方案改为每日一次（QD）单药方案（STR）Darunavir / Cobicistat / Emtricitabine / Tenofovir的功效和安全性在病毒学上被抑制HIV-1感染的成年人中Alafenamide（D / C / F / TAF）：第3周随机非自卑性EMERALD试验的第96周结果
6. Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV‐infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine [O] . Purificación Cid‐Silva, Noelia Fernández‐Bargiela, Luis Margusino‐Framiñán, 2018

机译：用替诺福韦富马酸盐治疗富马酸盐使艾滋病毒感染患者的脂质曲线与替诺福韦解毒富马酸盐进行治疗，每种与Elvitegravir，Cobicistat和Emtrickabine的Coformulated

A randomized, double-blind comparison of tenofovir alafenamide versus tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine for initial HIV-1 treatment: Week 96 results

著录项

引文网络

相似文献

相关主题

期刊订阅